To include your compound in the COVID-19 Resource Center, submit it here.

VicOryx: Phase I/IIa data

An open-label, German Phase I/IIa trial in 26 patients with p16INK4a-overexpressing

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE